Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 12, 2019 at 06:42 am
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was TWD 256.578 million compared to TWD 243.504 million a year ago. Operating income was TWD 19.463 million compared to TWD 13.335 million a year ago. Net income was TWD 16.410 million compared to TWD 16.062 million a year ago. Basic earnings per share was TWD 0.29 compared to TWD 0.28 a year ago. For the nine months, total revenue was TWD 756.258 million compared to TWD 725.618 million a year ago. Operating income was TWD 60.079 million compared to TWD 34.634 million a year ago. Net income was TWD 51.057 million compared to TWD 35.926 million a year ago. Basic earnings per share was TWD 0.9 compared to TWD 0.63 a year ago. Diluted earnings per share was TWD 0.89 compared to TWD 0.63 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
